Homology Medicines, Inc. (FIXX): Price and Financial Metrics
Homology Medicines, Inc. (FIXX)
Today's Latest Price: $13.00 USD
Updated Jan 27 8:58am
Add FIXX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
FIXX Stock Summary
- Homology Medicines Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 9.58% of US listed stocks.
- FIXX's went public 2.84 years ago, making it older than just 8.05% of listed US stocks we're tracking.
- FIXX's price/sales ratio is 258.31; that's higher than the P/S ratio of 97.85% of US stocks.
- If you're looking for stocks that are quantitatively similar to Homology Medicines Inc, a group of peers worth examining would be EVGN, ARCT, GRTS, AUTL, and QURE.
- Visit FIXX's SEC page to see the company's official filings. To visit the company's web site, go to www.homologymedicines.com.
FIXX Stock Price Chart Interactive Chart >
FIXX Price/Volume Stats
| Current price | $13.00 | 52-week high | $22.38 |
| Prev. close | $13.04 | 52-week low | $8.70 |
| Day low | $13.00 | Volume | 304 |
| Day high | $13.00 | Avg. volume | 282,459 |
| 50-day MA | $11.36 | Dividend yield | N/A |
| 200-day MA | $12.49 | Market Cap | 588.43M |
Homology Medicines, Inc. (FIXX) Company Bio
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.
Loading social stream, please wait...